Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as an injection for intramuscular, intravenous, and subcutaneous use. It is approved in the European Union and classified as prescription‑only. The drug works by interfering with folate metabolism, which limits rapid cell proliferation.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide and adheres to stringent quality standards.

Methotrexate is used in several autoimmune and oncologic conditions that involve abnormal cell proliferation.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: improves skin lesions and decreases plaque formation. Acute lymphoblastic leukemia: induces remission by inhibiting malignant lymphoblast growth. Non‑Hodgkin lymphoma: contributes to tumor control as part of combination chemotherapy. Gestational trophoblastic disease: eradicates trophoblastic tissue and prevents disease recurrence.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Oral ulcers or mucositis - Mild elevation of liver enzymes - Decreased white blood cell count - Headache

Serious or Rare Side Effects: - Severe liver toxicity or hepatitis - Pulmonary fibrosis or interstitial pneumonitis - Bone marrow aplasia leading to pancytopenia - Life‑threatening infections - Acute renal failure - Cutaneous necrosis or severe skin reactions

When using Metoject, several precautions should be observed to minimize risk.

Pregnancy: contraindicated (Category X) – avoid use in pregnant patients. Renal impairment: assess kidney function before initiation and adjust as needed. Hepatic impairment: monitor liver enzymes regularly during therapy. Hematologic monitoring: perform complete blood counts frequently to detect bone‑marrow suppression. Drug interactions: review concomitant medications for potential additive toxicity. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - NSAIDs: increase risk of hematologic toxicity. - Trimethoprim‑sulfamethoxazole: enhances myelosuppression. - Pemetrexed: additive antimetabolite effects. - Proton pump inhibitors: may affect absorption (rare).

Moderate Interactions (Monitor Closely): - Penicillins: possible increased toxicity. - Sulfonamides: may augment bone‑marrow suppression. - Alcohol: heightens liver toxicity risk. - Phenytoin: may reduce methotrexate clearance. - Azathioprine: combined immunosuppression requires monitoring.